HomeCompareLIAN vs EPRT

LIAN vs EPRT: Dividend Comparison 2026

LIAN yields 134.80% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LIAN wins by $14.65M in total portfolio value
10 years
LIAN
LIAN
● Live price
134.80%
Share price
$0.32
Annual div
$0.43
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14.72M
Annual income
$5,984,170.20
Full LIAN calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — LIAN vs EPRT

📍 LIAN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLIANEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LIAN + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LIAN pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LIAN
Annual income on $10K today (after 15% tax)
$11,457.68/yr
After 10yr DRIP, annual income (after tax)
$5,086,544.67/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, LIAN beats the other by $5,075,630.05/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LIAN + EPRT for your $10,000?

LIAN: 50%EPRT: 50%
100% EPRT50/50100% LIAN
Portfolio after 10yr
$7.39M
Annual income
$2,998,505.46/yr
Blended yield
40.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

LIAN
Analyst Ratings
1
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
-2.4
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LIAN buys
0
EPRT buys
0
No recent congressional trades found for LIAN or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLIANEPRT
Forward yield134.80%3.92%
Annual dividend / share$0.43$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$14.72M$63.4K
Annual income after 10y$5,984,170.20$12,840.73
Total dividends collected$13.51M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: LIAN vs EPRT ($10,000, DRIP)

YearLIAN PortfolioLIAN Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$24,180$13,479.62$11,205$505.18+$13.0KLIAN
2$56,333$30,460.96$12,672$682.46+$43.7KLIAN
3$126,601$66,324.55$14,490$930.48+$112.1KLIAN
4$274,767$139,304.02$16,786$1,282.69+$258.0KLIAN
5$576,559$282,557.87$19,753$1,791.56+$556.8KLIAN
6$1,171,036$554,118.18$23,677$2,541.64+$1.15MLIAN
7$2,304,838$1,051,829.48$29,008$3,672.99+$2.28MLIAN
8$4,400,957$1,934,780.61$36,463$5,425.08+$4.36MLIAN
9$8,161,691$3,452,667.04$47,238$8,221.57+$8.11MLIAN
10$14,717,180$5,984,170.20$63,385$12,840.73+$14.65MLIAN

LIAN vs EPRT: Complete Analysis 2026

LIANStock

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Full LIAN Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this LIAN vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LIAN vs SCHDLIAN vs JEPILIAN vs OLIAN vs KOLIAN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.